@article{3156747,
    title = "Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel
in patients with metastatic castration-resistant prostate cancer
(mCRPC): Results from the randomized phase III READY trial",
    author = "Araujo, John C. and Trudel, Geralyn C. and Saad, Fred and Armstrong, and Andrew J. and Yu, Evan Y. and Bellmunt, Joaquim and Wilding, George and and McCaffrey, John and Serrano, Sergio V. and Matveev, Vsevolod and and Efstathiou, Eleni and Oudard, Stephane and Morris, Michael J. and Sizer, and Bruce and Goebell, Peter J. and De Bono, Johann Sebastian and Paliwal, and Prashni and Durham, Susan and Cheng, Shinta and Logothetis, Christopher",
    journal = "World Journal of Clinical Oncology",
    year = "2013",
    volume = "31",
    number = "6, S",
    publisher = "AMER SOC CLINICAL ONCOLOGY 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA",
    doi = "10.1200/jco.2013.31.6_suppl.lba8"
}